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Myoclonic epilepsy associated with ragged-red ﬁbers (MERRF) is a
multisystem disorder caused by a mutation in the mitochondrial DNA
(mtDNA) gene MT-TK. The most common pathogenic variant is an A-
to-G transition at nucleotide 8344 (m.8344ANG). However, the occur-
rence of “heteroplasmy” can result in varying tissue distribution of mu-
tated mtDNA, and lead to varying symptoms (Hammans et al., 1993;
Enriquez et al., 1995). In this study, PBMCs were obtained from an 11-
years-old MERRF patient with m.8344ANG mutation in the MT-TK al-
lele. Using Sendai virus containing the reprogramming factors Oct3/4,
Sox2, cMyc, Klf4, the human MERRF iPSC lines were generated from63.com (Z. Xu).
. This is an open access article underthe PBMCs non-integratively (Fig. 1A). The iPSC line described in this
publication was named iMERRF-C7. Five additional clones from the
same patient were also isolated and characterized (data not shown).
All iMERRF-C7 iPSCs stained positive for the pluripotency markers
SSEA-4, TRA-1-60 and TRA-1-81 at passage of 10 (Fig. 1B), illustrating
the purity of the iPSC line. Accordingly, the expression of the other
pluripotency genes OCT4, SOX2, C-MYC, NANOG and TERT was upregu-
lated in iPSCs compared to patient PBMCs, and the gene expression
levels were comparable to those of a characterized positive control H9
line (Fig. 1C). Pluripotency was supported by the capability of
iMERRF-C7 to differentiate into the three germ layers in vivo by terato-
ma assay (Fig. 1D). iMERRF-C7 had a normal karyotype (46, XX), and
had no copy number variation larger than 300 kb analyzed by SNP-
array (Fig. 1E). The co-existence of the m.8344ANG mutation and wild
type allele in both iMERRF-C7 and patient PBMCs was conﬁrmed by
Sanger sequencing. The heteroplasmic level of iMERRF-C7 was mea-
sured by pyrosequencing the mitochondrial DNA ﬂanking m.8344 loci,
which is about the same level compared to the primary patient PBMCs
(Fig. 1F). Additionally, there are variations of the m.8344 heteroplasmic
levels in the other iPSC lines generated from the same patient, including
one line with nomutant allele (Table S1), which is similar with the pre-
vious study (Fujikura et al., 2012).
Materials and methods
Reprogramming of PBMCs to iPSCs
Written informed consent was obtained from the MERRF patient
and the study was approved by the scientiﬁc ethical committee in Ob-
stetrics and Gynecology Hospital Afﬁliated to NanjingMedical Universi-
ty. Peripheral blood was taken from the 11-years-old female MERRF
patient with m.8344ANG mutation. PBMC was isolated by density gra-
dient centrifugation with Histopaque Reagent (Sigma-Aldrich, USA).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Molecular and functional characterization of the iMERRF iPSC line. A. Reprogramming of theMERRF patient derived PBMC. Representative cells under a phase-contrastmicroscope.
Scalebars: 100 μm. B. Protein expression of pluripotency markers. Fluorescent immunocytochemistry for pluripotencymarkers was performed on iMERRF-C7 iPSCs. Scalebars: 100 μm. C.
Gene expression of pluripotencymarkers. Pluripotency gene expression was identiﬁed using RT-PCR. GAPDHwas used as a loading control. D. The differentiation potential to three germ
layers identiﬁed by in vivo teratoma assay. From left to right: ectoderm (neural tube), mesoderm (muscle), and endoderm (glands). Scalebars: 100 μm. E, Karyotyping and SNP-array.
Representative karyotype and SNP-array result of iMERRF-C7 iPSCs. F. The mitochondrial mutation and heteroplasmic level. Upper, Sanger sequencing result showing the A to G
mutation at the m.8344 loci in both primary cells and iMERRF-C7 iPSCs indicated by the arrows. Lower, Pyrosequencing result showing the similar mitochondrial heteroplasmic levels
before and after reprogramming, while arrows indicate the heteroplasmic levels.
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CytoTune 2.0 Sendai Reprogramming Kit (ThermoFisher Scientiﬁc,
USA). Brieﬂy, the isolated PBMCs were cultured for 4 days at 37 °C and
5% CO2 using StemPro-34 Medium (ThermoFisher Scientiﬁc) added
with 100 ng/ml SCF, 100 ng/ml FLT-3, 20 ng/ml IL-3 and 20 ng/ml IL-6
(ThermoFisher Scientiﬁc). On the day of transduction, 3 × 105 cells
were harvested and transduced using the CytoTune 2.0 Sendai
reprogramming vectors (KOS MOI = 6, hc-Myc MOI = 6, hKlf4
MOI= 4, ThermoFisher Scientiﬁc). The transducted cells were cultured
in StemPro-34 Medium for 2 days, and then seeded on hESC-qualiﬁed
matrigel (BD Biosciences, USA) coated plates in Essential 8 medium
(ThermoFisher Scientiﬁc). On days 21–28 after transduction, single
iPSC colonies were manually cut and passaged. From passage 5, iPSCs
were split every 4–7 days with 0.5 mMEDTA (ThermoFisher Scientiﬁc).The iPSC lineswere frozen in Essential 8mediumwith 10%DMSOor cul-
tured for further tests.
Fluorescent immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (PFA) for 30 min at room
temperature, followed by three washes with PBS and permeabilization
with 1% Triton X-100 (Sigma) for 30 min. Cells were blocked in a solu-
tion containing 1% bovine serum albumin (BSA) in PBST for 1 h at
room temperature. Incubate with the primary antibody diluted in the
blocking buffer overnight at 4 °C. Primary antibodies were used as fol-
lows: SSEA4, TRA1-60, TRA1-8 (1:100 dilution, ThermoFisher Scientif-
ic). After washing 3 × 10 min with PBS, appropriate ﬂuorescence-
labeled secondary antibodies were diluted at 1:1000 in the blocking
Table 1
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618 D. Liang et al. / Stem Cell Research 17 (2016) 616–618buffer and incubated for 1 h at room temperature while protected from
light. After washing 3 × 10 min with PBS, the nuclei were counter-
stained with DAPI (Invitrogen) staining solution for 10 min at room
temperature. Results were visualized and imaged under the DMi8 ﬂuo-
rescent microscope (Leica, Germany).
Reverse transcript polymerase chain reaction (RT-PCR)
RNA of the iPS cells were isolated using Trizol LS Reagent
(Invitrogen) according to standard protocol. 1 μg RNA/reaction was re-
verse transcribed using RevertAid First Strand cDNA Sytnthesis Kit
(ThermoFisher Scientiﬁc) according tomanufacturer's protocol. Primers
are listed in Table 1.
Teratoma assay
The in vivo differentiation experiments (teratoma formation) were
performed by Cellapy Company (China, http://www.cellapy2013.
bioon.com.cn/). Brieﬂy, 3 aliquots of approximately 1 × 107 cells of the
P10 iPSCs were collected by 0.5 mM EDTA treatment. Cells were resus-
pended in PBS and immediately injected subcutaneously into 3 immu-
nodeﬁcient NOD-SCID mice (Charles River, China). The teratomas
were collected after 2 months, and processed using standard proce-
dures for parafﬁn embedding, followed by parafﬁn section and hema-
toxylin and eosin staining. Histological analysis was performed by a
pathologist.
Karyotyping and SNP-array
For cytogenetic analysis of the iPSC lines generated from theMERRF
patient, GTG banding at the 400 to 550-band level was performedaccording to a standard protocol. Twenty metaphases were counted
and karyograms were analyzed using cytovision software.
To detect any potential genomic abnormalities at a higher resolution,
SNP-arraywas performed. Brieﬂy, genomic DNAwas extracted from the
cells using the QIAamp DNA Mini Kit (Qiagen, Germany). The human
cyto12 SNP-array (Illumina, USA) comprising around 300,000 SNPs
was applied for the whole genome scan. Scanned images were then an-
alyzed and quantiﬁed by an algorithm with ﬁxed settings in BlueFuse
Multi Software (Illumina) (available protocol at www.cytochip.com).
Sanger sequencing and pyrosequencing
Point mutation in the mitochondrial DNA 8344 were identiﬁed
Sanger Sequencing. The fragmentsﬂanking them.8344 lociwere ampli-
ﬁed by PCR from the total DNA of primary cells or iPSCs, then PCR prod-
ucts were puriﬁed and sequenced on an ABI 3730xl DNA analyzer.
The heteroplasmy level of the primary PBMCs or iPSCs was deter-
mined by pyrosequencing. The primers for PCR ampliﬁcation and se-
quencing were designed using the software PryoMark Assay Design
(version 2.0, Qiagen). PCR was performed with primers biotinylated to
convert the PCR product to single-stranded DNA templates, using the
Vacuum Prep Tool. After PCR ampliﬁcation, pyrosequencing reactions
quantiﬁcation were performed using PyroMark Q96 ID (Qiagen) re-
agents, equipment, and software (version 2.0, Qiagen), according to
the manufacturer's instructions.
All the primers used are listed in Table 1.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.11.008.
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